Since these results are remarkably opposed to changes found in AD brains (20) and taking into account that QR2 is a removable memory constraint in rodents, we hypothesized that by selectively inhibiting QR2, age-related metabolic stress and cognitive decline may simultaneously be tackled, in parallel and in addition to ISR- and other existing therapeutic targets (2, 3, 21). Here, NQO2 is linked to Alzheimer disease.